Advanced in Sepsis

Dr. Mark R. Gilbert

Infectious Disease
Infectious Diseases Medical Associates LLC
1503 Lansdowne Ave, Suite 3010, 
Darby, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Sepsis
Infectious Diseases Medical Associates LLC
1503 Lansdowne Ave, Suite 3010, 
Darby, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Gilbert is an Infectious Disease provider in Darby, Pennsylvania. Dr. Gilbert is rated as an Advanced provider by MediFind in the treatment of Sepsis. His top areas of expertise are COVID-19, Pneumonia, Strep Throat, and Lymphangitis.

His clinical research consists of co-authoring 401 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Sepsis.

Specialties
Infectious Disease
Licenses
Internal Medicine in PA
Hospital Affiliations
Riddle Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

INFECTIOUS DISEASES MEDICAL ASSOCIATES LLC
1503 Lansdowne Ave, Suite 3010, Darby, PA 19023

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: ONC206
Study Phase: Phase 1
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Enrollment Status: Completed
Publish Date: December 08, 2025
Intervention Type: Other
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: TMZ, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Pembrolizumab, Temozolomide, Heat Shock Protein Peptide Complex-96 Vaccine
Study Phase: Phase 2
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Bevacizumab
Study Phase: Phase 2
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LB-100
Study Phase: Phase 2
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
View 8 Less Clinical Trials

401 Total Publications

Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.
Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.
Journal: Neuro-oncology advances
Published: October 01, 2025
Similar Doctors
Distinguished in Sepsis
Dr. Sarbjit Sandhu
Infectious Disease
Distinguished in Sepsis
Dr. Sarbjit Sandhu
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (50.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarbjit Sandhu is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Sandhu is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Bacterial Gastroenteritis, COVID-19, and Pneumonia.

Distinguished in Sepsis
Dr. Theodore Markou
Infectious Disease
Distinguished in Sepsis
Dr. Theodore Markou
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (50.9 miles away)
Languages Spoken:
English
See accepted insurances

Theodore Markou is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Markou is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Pneumonia, COVID-19, and Multisystem Inflammatory Syndrome in Children (MIS-C).

Distinguished in Sepsis
Dr. Fazila Aslam
Infectious Disease
Distinguished in Sepsis
Dr. Fazila Aslam
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (50.9 miles away)
Languages Spoken:
English
See accepted insurances

Fazila Aslam is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Aslam is rated as a Distinguished provider by MediFind in the treatment of Sepsis. Her top areas of expertise are Sepsis, Lymphangitis, Cellulitis, and Pneumonia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gilbert's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile